Online citations, reference lists, and bibliographies.
Referencing for people who value simplicity, privacy, and speed.
Get Citationsy
← Back to Search

Therapeutic Gold Compounds

S. Berners-Price, P. Barnard
Published 2014 · Chemistry

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
Whilst the application of gold in medicine is traceable for several thousand years and gold drugs have been used clinically to treat rheumatoid arthritis since the last century, there has been unprecedented recent interest in the design of gold compounds (both AuI and AuIII) to treat a wide range of different diseases. The stimulus for this research has been recognition of the unique chemistry of gold (high affinity for cysteine and selenocysteine residues) combined with the emergence of a variety of thiol and selenol protein drug targets, whose dysfunction in cells can cause or contribute to a variety of human diseases. In this Chapter we focus on the design of gold-based drugs and the role of ligands in controlling the reactivity of the metal centre, or in influencing cellular uptake and modulation of biological activity. We pay special attention to the design of AuI phosphine and N-heterocyclic compounds as antiarthritic and/or anticancer agents and their specific inhibition of enzyme targets such as thioredoxin reductase, the cathepsins and protein tyrosine phosphatases, as well as the role of ligand design in fine-tuning the reactivity of AuIII antitumour agents. We highlight also the opportunity to design gold drugs to target the emerging parasite drug targets in trypanosomes (African sleeping sickness, Chagas' disease and leishmaniasis), malaria-causing plasmodia and schistosomiasis, as well as exciting recent developments in the design of gold-based anticancer peptidomimetics for targeted drug delivery.
This paper references
Mechanism of toxicity of an experimental bidentate phosphine gold complexed antineoplastic agent in isolated rat hepatocytes.
P. F. Smith (1989)
Gold complexes as antitumor agents.
L. Messori (2004)
10.1007/s00775-008-0344-0
Inhibition of cathepsin B by Au(I) complexes: a kinetic and computational study
Shamila S. Gunatilleke (2008)
10.1007/BF03214805
China’s ancient gold drugs
Zhao Huai-zhi (2001)
10.1016/0049-0172(85)90037-X
The history of gold therapy in rheumatoid disease.
W. Kean (1985)
10.1016/J.JORGANCHEM.2005.07.013
Synthesis and structural characterisation of linear Au(I) N-heterocyclic carbene complexes: New analogues of the Au(I) phosphine drug Auranofin
M. Baker (2005)
10.1039/c0cc01058h
Gold(I) complex of N,N'-disubstituted cyclic thiourea with in vitro and in vivo anticancer properties-potent tight-binding inhibition of thioredoxin reductase.
Kun Yan (2010)
10.1039/c0dt01089h
[(C3H4N2)2Au]Cl--a bis protic gold(I)-NHC.
Peter C. Kunz (2011)
10.1039/c1cc10860c
Therapeutic applications of gold complexes: lipophilic gold(III) cations and gold(I) complexes for anti-cancer treatment.
Chi‐Ming Che (2011)
10.1039/B713917A
A cytotoxic bis(carbene)gold(I) complex of ferrocenyl complexes: synthesis and structural characterisation
U. E. Horvath (2008)
10.1016/S1040-8428(01)00216-5
Gold derivatives for the treatment of cancer.
E. R. Tiekink (2002)
10.1016/J.EJPHAR.2006.10.034
Cellular pharmacological properties of gold(III) porphyrin 1a, a potential anticancer drug lead.
Y. Wang (2007)
10.1007/BF03214618
Gold in medicine
G. Higby (1982)
10.1039/b924677k
Cysteine proteases as targets for metal-based drugs.
S. Fricker (2010)
10.1002/chem.201100321
Cytotoxicity of gold(I) N-heterocyclic carbene complexes assessed by using human tumor cell lines.
J. Weaver (2011)
10.1016/J.CCR.2009.02.026
Thioredoxin reductase: A target for gold compounds acting as potential anticancer drugs
A. Bindoli (2009)
10.1021/jm3000196
Synthesis, characterization, and in vitro studies of bis[1,3-diethyl-4,5-diarylimidazol-2-ylidene]gold(I/III) complexes.
W. Liu (2012)
10.1021/IC00215A026
Tertiary phosphine complexes of gold(I) and gold(III) with imido ligands: 1H, 31P, and 15N NMR spectroscopy, antiinflammatory activity, and X-ray crystal structure of (phthalimido)(triethylphosphine)gold(I)
S. J. Price (1985)
10.1002/cncr.24514
Gold (III) porphyrin complexes induce apoptosis and cell cycle arrest and inhibit tumor growth in colon cancer
Shuiping Tu (2009)
10.1016/j.jinorgbio.2007.10.019
Tuning the Au(I)-mediated inhibition of cathepsin B through ligand substitutions.
Shamila S. Gunatilleke (2008)
10.1021/jm100020w
Organometallic Anticancer Compounds
G. Gasser (2011)
In vivo antitumor activity and in vitro cytotoxic properties of bis[1,2-bis(diphenylphosphino)ethane]gold(I) chloride.
S. Berners-Price (1986)
10.1016/0162-0134(87)80062-4
Thiol competition for Et3PAuS-albumin: a nonenzymatic mechanism for Et3PO formation.
M. Coffer (1987)
10.1002/PMIC.200402027
Proteomic characterization of the cytotoxic mechanism of gold (III) porphyrin 1a, a potential anticancer drug
Y. Wang (2006)
10.1016/J.JINORGBIO.2006.07.006
A gold(I) complex with a vitamin K3 derivative: characterization and antitumoral activity.
J. Casas (2006)
10.1021/IC00105A016
Syntheses, Structures, and Spectroscopic Properties of Gold(I) Complexes of 1,3,5-Triaza-7-phosphaadamantane (TPA). Correlation of the Supramolecular Au.cntdot. .cntdot. .cntdot.Au Interaction and Photoluminescence for the Species (TPA)AuCl and [(TPA-HCl)AuCl]
Z. Assefa (1995)
10.1002/med.20168
Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies
S. Nobili (2010)
10.1515/BC.2007.037
Effects of disease-modifying anti-rheumatic drugs (DMARDs) on the activities of rheumatoid arthritis-associated cathepsins K and S
E. Weidauer (2007)
10.1039/c2cc36610j
Medicinal gold compounds form tight adducts with the copper chaperone Atox-1: biological and pharmacological implications.
C. Gabbiani (2012)
10.1021/JA9819763
CRYSTAL STRUCTURE OF THE ANTIARTHRITIC DRUG GOLD THIOMALATE (MYOCHRYSINE) : A DOUBLE-HELICAL GEOMETRY IN THE SOLID STATE
R. Bau (1998)
10.1016/s0021-9258(18)37942-0
Mechanism of alterations in isolated rat liver mitochondrial function induced by gold complexes of bidentate phosphines.
G. D. Hoke (1988)
10.1016/j.jinorgbio.2010.02.003
Synthesis, structure and cytotoxicity studies of four-coordinate bis (cis-bis(diphenylphosphino)ethene) gold(I) complexes, [Au(dppey)(2)]X.
P. Healy (2010)
10.1016/J.CCR.2009.01.032
The tumor proteasome as a novel target for gold(III) complexes: implications for breast cancer therapy.
V. Milacic (2009)
10.1021/IC0201856
Dinuclear Gold(I) Dithiophosphonate Complexes: Synthesis, Luminescent Properties, and X-ray Crystal Structures of [AuS2PR(OR‘)]2(R = Ph, R‘ = C5H9; R = 4-C6H4OMe, R‘ = (1S,5R,2S)-(−)-Menthyl; R = Fc, R‘ = (CH2)2O(CH2)2OMe)
W. V. Zyl (2002)
10.1016/j.jinorgbio.2011.08.026
Gold(I)-NHC complexes of antitumoral diarylimidazoles: structures, cellular uptake routes and anticancer activities.
L. Kaps (2012)
10.1146/ANNUREV.PHARMTOX.42.083001.144616
Protein tyrosine phosphatases: structure and function, substrate specificity, and inhibitor development.
Z. Zhang (2002)
10.1016/J.CCR.2009.02.019
On the medicinal chemistry of gold complexes as anticancer drugs
I. Ott (2009)
10.1039/c2cs35314h
Metal N-heterocyclic carbene complexes as potential antitumor metallodrugs.
W. Liu (2013)
10.1021/jm201480u
Toward the selective delivery of chemotherapeutics into tumor cells by targeting peptide transporters: tailored gold-based anticancer peptidomimetics.
M. N. Kouodom (2012)
10.1002/ijc.25311
Antitumor activity of gold(III)‐dithiocarbamato derivatives on prostate cancer cells and xenografts
L. Cattaruzza (2011)
10.1016/0041-008X(89)90315-3
In vivo and in vitro cardiotoxicity of a gold-containing antineoplastic drug candidate in the rabbit.
G. D. Hoke (1989)
10.1021/JM060436A
Structural and solution chemistry, antiproliferative effects, and DNA and protein binding properties of a series of dinuclear gold(III) compounds with bipyridyl ligands.
A. Casini (2006)
Treatment of HIV associated psoriatic arthritis with oral gold.
D. Shapiro (1996)
10.1002/ART.1780331001
The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses.
D. Felson (1990)
10.1038/448645A
New uses for old drugs
C. R. Chong (2007)
10.1021/CR980431O
Gold-Based Therapeutic Agents
C. F. Shaw (1999)
10.1021/jm800101w
Gold(I)-mediated inhibition of protein tyrosine phosphatases: a detailed in vitro and cellular study.
Divya Krishnamurthy (2008)
10.1039/B303294A
Gold(III) porphyrins as a new class of anticancer drugs: cytotoxicity, DNA binding and induction of apoptosis in human cervix epitheloid cancer cells.
C. Che (2003)
10.1039/c2dt32617e
N-Heterocyclic carbene metal complexes in medicinal chemistry.
Luciano Oehninger (2013)
10.1021/OM300475Y
Gold(I) Complexes Derived from Alkynyloxy-Substituted Anthraquinones: Syntheses, Luminescence, Preliminary Cytotoxicity, and Cell Imaging Studies
Rebeca G Balasingham (2012)
10.1039/c2cc30510k
Micelles based on gold-glycopolymer complexes as new chemotherapy drug delivery agents.
S. Pearson (2012)
10.1007/s00775-009-0558-9
Chemistry, antiproliferative properties, tumor selectivity, and molecular mechanisms of novel gold(III) compounds for cancer treatment: a systematic study
A. Casini (2009)
Prescribing trends in disease modifying antirheumatic drugs for rheumatoid arthritis: a survey of practicing Canadian rheumatologists.
J. Pope (2002)
10.1016/j.canlet.2010.01.033
Gold(III) porphyrin 1a inhibited nasopharyngeal carcinoma metastasis in vivo and inhibited cell migration and invasion in vitro.
C. Lum (2010)
10.1021/JM9601563
Antitumor properties of some 2-[(dimethylamino)methyl]phenylgold(III) complexes.
R. G. Buckley (1996)
10.1039/B305109A
Novel Au(III) complexes of aminoquinoline derivatives: crystal structure, DNA binding and cytotoxicity against melanoma and lung tumour cells
T. Yang (2003)
10.1021/JM0509288
Gold(III) dithiocarbamate derivatives for the treatment of cancer: solution chemistry, DNA binding, and hemolytic properties.
Luca Ronconi (2006)
10.1021/JM00281A001
Oral gold. Antiarthritic properties of alkylphosphinegold coordination complexes.
B. Sutton (1972)
10.1007/s10534-010-9293-5
HIV therapeutic possibilities of gold compounds
P. Fonteh (2010)
10.1371/JOURNAL.PMED.0040206
Thioredoxin Glutathione Reductase from Schistosoma mansoni: An Essential Parasite Enzyme and a Key Drug Target
Angela N Kuntz (2007)
10.1021/jm901220m
Identifying potent, selective protein tyrosine phosphatase inhibitors from a library of Au(I) complexes.
Mark R Karver (2009)
10.1021/JM049792O
Toward a novel metal-based chemotherapy against tropical diseases. 7. Synthesis and in vitro antimalarial activity of new gold-chloroquine complexes.
M. Navarro (2004)
10.1038/nm.2758
A high throughput drug screen for Entamoeba histolytica identifies a new lead and target
A. Debnath (2012)
10.1021/IC700861A
Novel gold(I) 7-azacoumarin complex: synthesis, structure, optical properties, and cytotoxic effects.
J. Casas, (2007)
10.1021/IC048260V
Gold dithiocarbamate derivatives as potential antineoplastic agents: design, spectroscopic properties, and in vitro antitumor activity.
Luca Ronconi (2005)
10.1016/J.BMCL.2006.01.027
Specific inhibitors of Plasmodium falciparum thioredoxin reductase as potential antimalarial agents.
A. D. Andricopulo (2006)
10.1002/ANIE.199721621
N-Heterocyclic Carbenes†‡
W. A. Herrmann (1997)
10.1016/J.BCP.2007.07.022
A gold(I) phosphine complex selectively induces apoptosis in breast cancer cells: implications for anticancer therapeutics targeted to mitochondria.
O. Rackham (2007)
10.1039/B602560A
Cationic, linear Au(I) N-heterocyclic carbene complexes: synthesis, structure and anti-mitochondrial activity.
M. Baker (2006)
10.1007/BF03215296
Gold(III) compounds as anticancer drugs
C. Gabbiani (2007)
10.1002/9783527633104.CH7
Gold-Based Therapeutic Agents: A New Perspective
S. Berners-Price (2011)
10.1039/b911234k
Synthesis and biological studies of some gold(I) complexes containing functionalised alkynes.
E. Schuh (2009)
10.1016/0049-0172(84)90029-5
Auranofin: a unique oral chrysotherapeutic agent.
R. C. Blodgett (1984)
10.1021/ic3013188
Synthesis and biological activity of ester- and amide-functionalized imidazolium salts and related water-soluble coinage metal N-heterocyclic carbene complexes.
M. Pellei (2012)
Screening trial with the coordinated gold compound auranofin using mouse lymphocyte leukemia P388.
T. M. Simon (1981)
10.1016/j.jinorgbio.2008.10.004
Outstanding plasmodicidal properties within a small panel of metallic compounds: Hints for the development of new metal-based antimalarials.
C. Gabbiani (2009)
10.1146/ANNUREV.CB.04.110188.001103
Mitochondrial membrane potential in living cells.
L. Chen (1988)
10.1016/j.jinorgbio.2011.09.006
Selected gold compounds cause pronounced inhibition of Falcipain 2 and effectively block P. falciparum growth in vitro.
N. Micale (2011)
10.1155/MBD.1998.245
Anti-Arthritic Activity in Rats of Some Phosphinegold(I) Thionucleobases and Related Thiolates
M. Whitehouse (1998)
10.1039/C2SC01127A
A spontaneous gold(I)-azide alkyne cycloaddition reaction yields gold-peptide bioconjugates which overcome cisplatin resistance in a p53-mutant cancer cell line
S. D. Koester (2012)
10.1039/c2dt31817b
Bromide ion binding by a dinuclear gold(I) N-heterocyclic carbene complex: a spectrofluorescence and X-ray absorption spectroscopic study.
Louise E. Wedlock (2013)
10.1021/cr8005153
Coinage metal-N-heterocyclic carbene complexes.
J. Y. Lin (2009)
10.1016/j.bcp.2009.07.023
Cancer cell death induced by phosphine gold(I) compounds targeting thioredoxin reductase.
V. Gandin (2010)
10.1021/jm300428v
Gold(I) carbene complexes causing thioredoxin 1 and thioredoxin 2 oxidation as potential anticancer agents.
E. Schuh (2012)
10.1039/B303297C
Chemical and biological studies of the dichloro(2-phenylpyridine) gold(III) complex and its derivatives
Darning Fan (2003)
10.1016/j.jinorgbio.2011.01.012
Inhibition of the cathepsin cysteine proteases B and K by square-planar cycloaurated gold(III) compounds and investigation of their anti-cancer activity.
Y. Zhu (2011)
10.1007/3-540-50130-4_2
Phosphines and metal phosphine complexes: Relationship of chemistry to anticancer and other biological activity
S. Berners-Price (1988)
10.1021/IC00265A032
Phosphorus-31 NMR studies of [Au2(.mu.-dppe)]2+ antitumor complexes. Conversion into [Au(dppe)2]+ induced by thiols and blood plasma
S. Berners-Price (1987)
10.1039/c0dt01057j
Bioinorganic and medicinal chemistry: aspects of gold(I)-protein complexes.
Krishna P Bhabak (2011)
10.1016/j.ejphar.2007.12.026
Gold(I) complexes determine apoptosis with limited oxidative stress in Jurkat T cells.
M. P. Rigobello (2008)
10.1039/c1mt00123j
Advances in metal-carbene complexes as potent anti-cancer agents.
A. Gautier (2012)
10.1039/c2cc37366a
A gold(III) porphyrin complex as an anti-cancer candidate to inhibit growth of cancer-stem cells.
C. Lum (2013)
10.1016/j.bcp.2007.11.024
Modulation of gold(III) porphyrin 1a-induced apoptosis by mitogen-activated protein kinase signaling pathways.
Y. Wang (2008)
10.1007/BF03214639
Gold compounds for rheumatoid arthritis
B. A. Sutton (1986)
10.1039/b307610e
Synthesis, characterization, and biological activities of 2-phenylpyridine gold(iii) complexes with thiolate ligandsElectronic supplementary information (ESI) available: ESMS data. See http://www.rsc.org/suppdata/dt/b3/b307610e/
Daming Fan (2003)
10.1007/s00011-003-1208-2
Chrysotherapy: a synoptic review
R. Eisler (2003)
10.1007/s10787-007-0018-5
Anti-cancer potential of gold complexes
E. Tiekink (2007)
10.1039/c0cc01465f
Reactions of medicinally relevant gold compounds with the C-terminal motif of thioredoxin reductase elucidated by MS analysis.
A. Pratesi (2010)
10.1039/c001216e
Cyclometalated gold(III) complexes with N-heterocyclic carbene ligands as topoisomerase I poisons.
J. Yan (2010)
10.1016/j.jinorgbio.2009.02.011
Synthesis and characterization of a pyridine-2-thiol N-oxide gold(I) complex with potent antiproliferative effect against Trypanosoma cruzi and Leishmania sp. insight into its mechanism of action.
M. Vieites (2009)
10.1016/j.jinorgbio.2008.05.010
Metal compounds for the treatment of parasitic diseases.
S. Fricker (2008)
10.1016/J.IJPARA.2003.09.011
Oxidative stress in malaria parasite-infected erythrocytes: host-parasite interactions.
K. Becker (2004)
10.1002/EJIC.201200147
Gold(I) complexes incorporating emissive mercapto-pteridine ligands: Syntheses, X-ray structure, luminescence and preliminary cytotoxic evaluation
L. A. Mullice (2012)
10.1002/MED.10051
The thioredoxin system—From science to clinic
S. Gromer (2004)
10.1158/0008-5472.CAN-06-3017
A novel anticancer gold(III) dithiocarbamate compound inhibits the activity of a purified 20S proteasome and 26S proteasome in human breast cancer cell cultures and xenografts.
V. Milacic (2006)
10.1021/cr800500u
The medicinal applications of imidazolium carbene-metal complexes.
Khadijah M. Hindi (2009)
10.1021/JM050493O
Mechanisms of cytotoxicity of selected organogold(III) compounds.
M. Coronnello (2005)
10.1021/OL990909Q
Synthesis and activity of a new generation of ruthenium-based olefin metathesis catalysts coordinated with 1,3-dimesityl-4,5-dihydroimidazol-2-ylidene ligands.
M. Scholl (1999)
10.1021/JA037012F
Emission energy correlates with inverse of gold-gold distance for various [Au(SCN)2]- salts.
Nathan L. Coker (2004)
Preclinical tolerance and pharmacokinetic assessment of MU-Gold, a novel chemotherapeutic agent, in laboratory dogs.
M. Higginbotham (2003)
10.1002/anie.201209787
Gold(III) complexes containing N-heterocyclic carbene ligands: thiol "switch-on" fluorescent probes and anti-cancer agents.
T. Zou (2013)
10.1039/c1cc11820j
Anticancer gold(I)-phosphine complexes as potent autophagy-inducing agents.
Songhai Tian (2011)
10.1021/JM00152A009
Correlation of the in vitro cytotoxic and in vivo antitumor activities of gold(I) coordination complexes.
C. Mirabelli (1986)
10.1039/c1mt00062d
Gold compounds as therapeutic agents for human diseases.
S. Berners-Price (2011)
10.1021/jm8012135
A gold(I) phosphine complex containing a naphthalimide ligand functions as a TrxR inhibiting antiproliferative agent and angiogenesis inhibitor.
I. Ott (2009)
10.1021/IC950343B
Chemical and Biological Studies of Dichloro(2-((dimethylamino)methyl)phenyl)gold(III).
R. Parish (1996)
10.1007/s00775-009-0466-z
Auranofin disrupts selenium metabolism in Clostridium difficile by forming a stable Au–Se adduct
S. Jackson-Rosario (2009)
10.1039/C39800001261
An EXAFS study of gold co-ordination in the anti-arthritic drugs Myocrisin and Solganol
M. Mazid (1980)
10.1071/CH08175
The Design of Gold-Based, Mitochondria-Targeted Chemotherapeutics
S. Berners-Price (2008)
10.1097/QAD.0b013e328347bd77
Gold drug auranofin restricts the viral reservoir in the monkey AIDS model and induces containment of viral load following ART suspension
M. Lewis (2011)
10.1186/1752-153X-6-68
Design, synthesis and structural studies of meta-xylyl linked bis-benzimidazolium salts: potential anticancer agents against ‘human colon cancer’
Rosenani A. Haque (2012)
10.1039/C3SC21972K
A dinuclear cyclometalated gold(III)–phosphine complex targeting thioredoxin reductase inhibits hepatocellular carcinoma in vivo
R. W. Sun (2013)
10.1021/JM990492U
Gold(III) complexes as potential antitumor agents: solution chemistry and cytotoxic properties of some selected gold(III) compounds.
L. Messori (2000)
Evaluation of the in vivo antitumor activity and in vitro cytotoxic properties of auranofin, a coordinated gold compound, in murine tumor models.
C. Mirabelli (1985)
10.1002/anie.201202939
On the biological properties of alkynyl phosphine gold(I) complexes.
A. Meyer (2012)
10.1074/jbc.M606054200
Aurothiomalate Inhibits Transformed Growth by Targeting the PB1 Domain of Protein Kinase Cι*
E. Erdoğan (2006)
10.1021/ic902335z
Seleno-auranofin (Et3PAuSe-tagl): synthesis, spectroscopic (EXAFS, 197Au Mössbauer, 31P, 1H, 13C, and 77Se NMR, ESI-MS) characterization, biological activity, and rapid serum albumin-induced triethylphosphine oxide generation.
D. Hill (2010)
10.1007/978-1-4613-2837-7_23
The Design of Metal Complexes as Anticancer Drugs
P. Sadler (1984)
10.1039/b804026p
Water-soluble cyclodiphosphazanes: synthesis, gold(I) metal complexes and their in vitro antitumor studies.
D. Suresh (2008)
10.1021/OM1001292
Novel Sulfonated N-Heterocyclic Carbene Gold(I) Complexes: Homogeneous Gold Catalysis for the Hydration of Terminal Alkynes in Aqueous Media
A. Almássy (2010)
10.1016/j.febslet.2008.02.028
New uses for old drugs. Auranofin, a clinically established antiarthritic metallodrug, exhibits potent antimalarial effects in vitro: Mechanistic and pharmacological implications
A. Sannella (2008)
10.1002/anie.201108466
Organogold(III) supramolecular polymers for anticancer treatment.
J. Zhang (2012)
10.1016/j.jinorgbio.2012.07.001
Rational design of gold(III)-dithiocarbamato peptidomimetics for the targeted anticancer chemotherapy.
M. N. Kouodom (2012)
10.1002/1521-3773(20020415)41:8<1290::AID-ANIE1290>3.0.CO;2-Y
N-heterocyclic carbenes: a new concept in organometallic catalysis.
W. A. Herrmann (2002)
10.1016/J.CCR.2008.12.003
Gold complexes as potential anti-parasitic agents
M. Navarro (2009)
10.1016/J.CCR.2007.04.006
Targeting the mitochondrial cell death pathway with gold compounds
P. Barnard (2007)
10.3109/0284186X.2010.537693
Gold(III) porphyrin 1a prolongs the survival of melanoma-bearing mice and inhibits angiogenesis
C. Lum (2011)
10.1016/J.POLY.2011.12.026
Neutral mononuclear and dinuclear complexes of gold(I) featuring azole ligands: synthesis, structure and cytotoxicity
W. F. Gabrielli (2012)
10.1039/B316804B
Dinuclear gold(I) complexes of bridging bidentate carbene ligands: synthesis, structure and spectroscopic characterisation.
P. Barnard (2004)
10.1007/s002800000166
Role of lipophilicity in determining cellular uptake and antitumour activity of gold phosphine complexes
M. McKeage (2000)
10.1021/ja804027j
Mitochondria-targeted chemotherapeutics: the rational design of gold(I) N-heterocyclic carbene complexes that are selectively toxic to cancer cells and target protein selenols in preference to thiols.
J. Hickey (2008)
10.1016/J.JINORGBIO.2007.09.003
In vitro antitumour and hepatotoxicity profiles of Au(I) and Ag(I) bidentate pyridyl phosphine complexes and relationships to cellular uptake.
J. Liu (2008)
10.1016/j.jinorgbio.2010.10.016
In vitro antitumour activity of water soluble Cu(I), Ag(I) and Au(I) complexes supported by hydrophilic alkyl phosphine ligands.
C. Santini (2011)
10.1016/J.IJPARA.2004.10.003
Cysteine proteases of malaria parasites.
P. Rosenthal (2004)
A study into the chemistry, spectroscopic properties, and subcellular distribution of some gold(I) complexes of pharmacological interest
Louise E. Wedlock (2010)
10.1021/ic701254s
Structural characterization, solution studies, and DFT calculations on a series of binuclear gold(III) oxo complexes: relationships to biological properties.
C. Gabbiani (2008)
10.1016/J.JINORGBIO.2007.07.034
Synthesis, structure and cytotoxicity of triphenylphosphinegold(I) sulfanylpropenoates.
E. Barreiro (2008)
10.1007/s00775-006-0120-y
DNA binding properties of novel cytotoxic gold(III) complexes of terpyridine ligands: the impact of steric and electrostatic effects
P. Shi (2006)
10.1021/jm201156x
NHC gold halide complexes derived from 4,5-diarylimidazoles: synthesis, structural analysis, and pharmacological investigations as potential antitumor agents.
W. Liu (2011)
10.1039/B705008A
Gold(I) chloride adducts of 1,3-bis(di-2-pyridylphosphino)propane: synthesis, structural studies and antitumour activity.
A. S. Humphreys (2007)
10.1021/JM00395A004
Antitumor activity of bis(diphenylphosphino)alkanes, their gold(I) coordination complexes, and related compounds.
C. Mirabelli (1987)
10.1021/JM060158F
Inhibition of lysosomal cysteine proteases by a series of Au(I) complexes: a detailed mechanistic investigation.
Shamila S. Gunatilleke (2006)
10.1002/ANIE.200300639
Dithiol proteins as guardians of the intracellular redox milieu in parasites: old and new drug targets in trypanosomes and malaria-causing plasmodia.
R. L. Krauth-Siegel (2005)
10.1128/jb.00164-09
Inhibition of selenium metabolism in the oral pathogen Treponema denticola.
S. Jackson-Rosario (2009)
10.1039/c2mt00083k
Proteomic analysis of ovarian cancer cell responses to cytotoxic gold compounds.
F. Guidi (2012)
10.1016/S0166-6851(02)00031-2
The disulfide redox system of Schistosoma mansoni and the importance of a multifunctional enzyme, thioredoxin glutathione reductase.
Heather M Alger (2002)
10.1016/J.JORGANCHEM.2010.10.054
Synthesis and anticancer properties of gold(I) and silver(I) N-heterocyclic carbene complexes
Tammy J. Siciliano (2011)
10.1016/S0169-409X(01)00125-9
Delocalized lipophilic cations selectively target the mitochondria of carcinoma cells.
J. Modica-Napolitano (2001)
10.1021/ja00324a019
Bovine serum albumin-gold thiomalate complex: gold-197 Moessbauer, EXAFS and XANES, electrophoresis, sulfur-35 radiotracer, and fluorescent probe competition studies
C. F. Shaw (1984)
10.1016/j.jinorgbio.2007.11.003
Gold(III) compounds as anticancer agents: relevance of gold-protein interactions for their mechanism of action.
A. Casini (2008)
10.1039/c1dt10368g
Gold(I) complexes of water-soluble diphos-type ligands: synthesis, anticancer activity, apoptosis and thioredoxin reductase inhibition.
C. Wetzel (2011)
10.1007/s00775-010-0624-3
Exploring the biochemical mechanisms of cytotoxic gold compounds: a proteomic study
F. Magherini (2010)
10.1158/0008-5472.CAN-05-3405
A novel small-molecule inhibitor of protein kinase Cι blocks transformed growth of non-small-cell lung cancer cells
Melody L Stallings-Mann (2006)
10.1016/j.drudis.2010.10.005
Metal-based drugs for malaria, trypanosomiasis and leishmaniasis: recent achievements and perspectives.
M. Navarro (2010)
10.1016/J.JINORGBIO.2005.12.020
Gold(III) compounds of 1,4,7-triazacyclononane showing high cytotoxicity against A-549 and HCT-116 tumor cell lines.
P. Shi (2006)
10.1021/JM00167A017
Cytotoxicity and antitumor activity of some tetrahedral bis(diphosphino)gold(I) chelates.
S. Berners-Price (1990)
10.1021/OM100300A
Antiproliferative Activity of Gold(I) Alkyne Complexes Containing Water-Soluble Phosphane Ligands
E. Vergara (2010)
10.1021/cr900074m
N-heterocyclic carbenes in late transition metal catalysis.
Silvia Díez-González (2009)
10.1002/CHEM.200600117
Anticancer Cyclometalated [AuIIIm(C∧N∧C)mL]n+ Compounds: Synthesis and Cytotoxic Properties
C. K. Li (2006)
10.1002/EJIC.201001195
Synthesis, Structure and Bactericide Activity of (Aminophosphane)gold(I) Thiolate Complexes
M. Fillat (2011)
10.1038/sj.bjc.6605147
Inhibition of Akt sensitises neuroblastoma cells to gold(III) porphyrin 1a, a novel antitumour drug induced apoptosis and growth inhibition
W. Li (2009)
10.1016/J.BMC.2004.09.014
Solution chemistry and cytotoxic properties of novel organogold(III) compounds.
L. Messori (2004)
10.1016/J.CCR.2009.02.017
The anti-cancer properties of gold(III) compounds with dianionic porphyrin and tetradentate ligands
R. W. Sun (2009)
10.1002/ANIE.200502756
Undressing of phosphine gold(I) complexes as irreversible inhibitors of human disulfide reductases.
Sabine Urig (2006)
10.1021/jm201220n
Comparative in vitro evaluation of N-heterocyclic carbene gold(I) complexes of the benzimidazolylidene type.
R. Rubbiani (2011)
10.1016/J.JINORGBIO.2004.05.011
Mitochondrial permeability transition induced by dinuclear gold(I)-carbene complexes: potential new antimitochondrial antitumour agents.
P. Barnard (2004)
10.1039/b906140a
Synthesis, structural characterisation and anti-proliferative activity of NHC gold amino acid and peptide conjugates.
J. Lemke (2009)
10.1016/j.jinorgbio.2010.06.005
Synthesis and in vitro evaluation of gold(I) thiosemicarbazone complexes for antimalarial activity.
Setshaba D Khanye (2010)
10.1021/jm3009822
A soluble bis-chelated gold(I) diphosphine compound with strong anticancer activity and low toxicity.
Y. Wang (2013)
10.2165/00003495-198427050-00002
Auranofin. A preliminary review of its pharmacological properties and therapeutic use in rheumatoid arthritis.
M. Chaffman (1984)
10.1016/J.CHEMBIOL.2007.08.016
Gold(III)-dithiocarbamato complexes induce cancer cell death triggered by thioredoxin redox system inhibition and activation of ERK pathway.
D. Saggioro (2007)
10.1016/S0010-8545(02)00048-6
Mechanisms of cytotoxicity and antitumor activity of gold(I) phosphine complexes: the possible role of mitochondria
M. McKeage (2002)
10.1002/ANIE.200601526
Luminescence studies of the intracellular distribution of a dinuclear gold(I) N-heterocyclic carbene complex.
P. Barnard (2006)
10.1002/1097-0142(197912)44:6<1965::AID-CNCR2820440602>3.0.CO;2-6
Inhibitory effects of a new oral gold compound on hela cells
T. M. Simon (1979)
10.1021/JM025615G
In vitro and in vivo antitumor properties of tetrakis((trishydroxy- methyl)phosphine)gold(I) chloride.
Nagavarakishore Pillarsetty (2003)
10.1039/b912378d
Naphthalimide gold(I) phosphine complexes as anticancer metallodrugs.
C. Bagowski (2009)
10.1002/cmdc.200900370
Anticancer Therapeutics That Target Selenoenzymes: Synthesis, Characterization, in vitro Cytotoxicity, and Thioredoxin Reductase Inhibition of a Series of Gold(I) Complexes Containing Hydrophilic Phosphine Ligands
Elena Vergara (2010)
10.1016/j.bmc.2009.10.034
Antitumor activity of diethynylfluorene derivatives of gold(I).
C. Chui (2009)
10.1021/jm201416p
Anti-inflammatory active gold(I) complexes involving 6-substituted-purine derivatives.
Z. Trávníček (2012)
10.1002/cmdc.200800210
A Sugar‐Modified Phosphole Gold Complex with Antiproliferative Properties Acting as a Thioredoxin Reductase Inhibitor in MCF‐7 Cells
E. Viry (2008)
10.1039/c1dt10578g
Cytotoxic gold(I)-bearing dendrimers from alkyne precursors.
Thomas J. Robilotto (2011)
10.1039/B705551J
Metal based drugs: from serendipity to design.
S. P. Fricker (2007)
10.1007/s00726-011-0997-9
A gold-containing drug against parasitic polyamine metabolism: the X-ray structure of trypanothione reductase from Leishmania infantum in complex with auranofin reveals a dual mechanism of enzyme inhibition
A. Ilari (2011)
10.1021/JA00303A049
EXAFS and WAXS structure determination for an antiarthritic drug, sodium gold(I) thiomalate
R. Elder (1985)
10.1039/c2dt11781a
Synthesis and characterization of azolate gold(I) phosphane complexes as thioredoxin reductase inhibiting antitumor agents.
R. Galassi (2012)
10.1039/c1dt10892a
Thiolato gold(I) complexes containing water-soluble phosphane ligands: a characterization of their chemical and biological properties.
E. Vergara (2011)
10.1002/ijc.24130
Gold(III) porphyrin complex is more potent than cisplatin in inhibiting growth of nasopharyngeal carcinoma in vitro and in vivo
Y. F. To (2009)
10.1021/JM010997W
Gold(III) complexes with bipyridyl ligands: solution chemistry, cytotoxicity, and DNA binding properties.
G. Marcon (2002)
10.1021/jm100801e
Benzimidazol-2-ylidene gold(I) complexes are thioredoxin reductase inhibitors with multiple antitumor properties.
R. Rubbiani (2010)
10.1016/j.jinorgbio.2009.12.012
Gold(I) phosphine mediated selective inhibition of lymphoid tyrosine phosphatase.
Mark R Karver (2010)
10.1158/0008-5472.CAN-05-2867
Gold(III) Porphyrin 1a Induced Apoptosis by Mitochondrial Death Pathways Related to Reactive Oxygen Species
Y. Wang (2005)
10.1002/ijc.21484
Gold(III) compound is a novel chemocytotoxic agent for hepatocellular carcinoma
Ching Tung Lum (2006)



This paper is referenced by
10.2174/0929867323666160504103843
Gold Complexes for Therapeutic Purposes: an Updated Patent Review (2010-2015).
C. Nardon (2016)
10.1073/pnas.1915202117
An anticancer gold(III)-activated porphyrin scaffold that covalently modifies protein cysteine thiols
Ka-Chung Tong (2020)
10.1016/j.ejmech.2019.04.032
Perspectives of medicinally privileged chalcone based metal coordination compounds for biomedical applications.
D. K. Mahapatra (2019)
10.1002/EJIC.201801297
Heterobimetallic PtII‐AuI Complexes Comprising Unsymmetrical 1,1‐Bis(diphenylphosphanyl)methane Bridges: Synthesis, Photophysical, and Cytotoxic Studies
H. Shahsavari (2019)
10.1002/anie.202000528
Cyclometalated Gold(III)-Hydride Complexes Exhibit Visible Light-Induced Thiol Reactivity and Act as Potent Photo-Activated Anti-Cancer Agents.
Hejiang Luo (2020)
10.1016/j.jinorgbio.2017.11.004
Chloro(triphenylphosphine)gold(I) a forefront reagent in gold chemistry as apoptotic agent for cancer cells.
M. P. Chrysouli (2018)
10.1039/C9NJ02502B
Synthesis and biological evaluation of thiolate gold(I) complexes as thioredoxin reductase (TrxR) and glutathione reductase (GR) inhibitors
Masood Fereidoonnezhad (2019)
10.1039/c5sc03519h
Targeting antioxidant pathways with ferrocenylated N-heterocyclic carbene supported gold(i) complexes in A549 lung cancer cells† †Electronic supplementary information (ESI) available. CCDC 1419940 and 1419941. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/c5sc0
J. Arambula (2016)
Semantic Scholar Logo Some data provided by SemanticScholar